A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies

Trial Profile

A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2016

At a glance

  • Drugs Acalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 16 May 2016 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov
    • 04 Dec 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top